Puma Biotechnology Reports Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Puma Biotech (PBYI) Tops Q3 EPS by 13c, Misses on Revenue
November 7, 2024 5:04 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q3 EPS of $0.46, $0.13 better than the analyst estimate of $0.33. Revenue for the quarter came in at $80.5 million versus the consensus estimate of $70.65 million.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
... More